Andere Kunden interessierten sich auch für
![Endoscopy in Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics of North America]( "Endoscopy in Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics of North America")
Endoscopy in Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics of North America153,99 €![Complementary and Alternative Medicine in Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics of North America]( "Complementary and Alternative Medicine in Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics of North America")
Complementary and Alternative Medicine in Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics of North America118,99 €![Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics]( "Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics")
Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics155,99 €![Pediatric Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics of North America]( "Pediatric Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics of North America")
Pediatric Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics of North America117,99 €![Nonpolypoid Colorectal Neoplasms in Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics]( "Nonpolypoid Colorectal Neoplasms in Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics")
Nonpolypoid Colorectal Neoplasms in Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics118,99 €![Inflammatory Bowel Disease, an Issue of Surgical Clinics]( "Inflammatory Bowel Disease, an Issue of Surgical Clinics")
Inflammatory Bowel Disease, an Issue of Surgical Clinics118,99 €![Challenges in Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics]( "Challenges in Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics")
Challenges in Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics118,99 €
By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.